About exagen inc - XGN
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.
XGN At a Glance
Exagen, Inc.
1261 Liberty Way
Vista, California 92081
| Phone | 1-760-560-1501 | Revenue | 66.58M | |
| Industry | Medical/Nursing Services | Net Income | -19,951,000.00 | |
| Sector | Health Services | 2025 Sales Growth | 19.651% | |
| Fiscal Year-end | 12 / 2026 | Employees | 216 | |
| View SEC Filings |
XGN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.969 |
| Price to Book Ratio | 7.983 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -10.586 |
| Enterprise Value to Sales | 1.90 |
| Total Debt to Enterprise Value | 0.219 |
XGN Efficiency
| Revenue/Employee | 308,217.593 |
| Income Per Employee | -92,365.741 |
| Receivables Turnover | 6.133 |
| Total Asset Turnover | 1.273 |
XGN Liquidity
| Current Ratio | 3.453 |
| Quick Ratio | 3.22 |
| Cash Ratio | 2.276 |
XGN Profitability
| Gross Margin | 58.279 |
| Operating Margin | -21.134 |
| Pretax Margin | -29.891 |
| Net Margin | -29.968 |
| Return on Assets | -38.148 |
| Return on Equity | -147.845 |
| Return on Total Capital | -44.223 |
| Return on Invested Capital | -54.441 |
XGN Capital Structure
| Total Debt to Total Equity | 158.553 |
| Total Debt to Total Capital | 61.323 |
| Total Debt to Total Assets | 46.732 |
| Long-Term Debt to Equity | 141.338 |
| Long-Term Debt to Total Capital | 54.665 |